Skip to main content

Table 1 Demographic characteristics

From: Reliability, repeatability, and reproducibility of pulmonary transit time assessment by contrast enhanced echocardiography

  Mean ± SD (n = 15) Min – max (n = 15)
Gender (n male/women) 12/3  
Age (yr) 67 ± 7 58–78
Weight (kg) 81 ± 15 51–109
Height (cm) 176 ± 9 158–188
BMI 26 ± 4 19–37
BSA 2.0 ± 0.2 1.5–2.3
NYHA classification n (%)   
Class II 7 (47)  
Class III 5 (33)  
Class IV 3 (20)  
Echocardiography   
  LVEF (%) 31 ± 11 17–53
  RV dysfunction   
  TAPSE < 16 mm (n) 4/15  
  Pulmonary hypertension   
  TR velocity > 2.8 m/s (n) 2/15  
Electrocardiogram   
  Heart rate 72 ± 17 50–110
  QRS duration (ms) 151 ± 27 118–194
  IVMD (ms) in 13 patients 42 ± 14 20–60
  SPWMD (ms) in 11 patients 152 ± 70 10–240
Comorbidities n (%)   
  Hypertension 5 (33)  
  Coronary artery disease 11 (73)  
  Congestive heart failure 14 (93)  
  COPD 6 (40)  
  Diabetes mellitus 3 (20)  
Medication n (%)   
  Beta-blocker 12 (80)  
  ACE inhibitors 11 (73)  
  AT II blockers 2 (13)  
  Loop diuretics 12 (80)  
  K-sparing agents 6 (40)  
  Statins 14 (93)  
Laboratory   
  Creatinine (μmol/L) 105 ± 28 31–160
  NT-proBNP (pmol/L) 162 ± 111 36–440
  1. SD standard deviation, BMI body mass index, BSA body surface area, NYHA New York Heart Association, LVEF left ventricular ejection fraction, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, TR tricuspid regurgitation, IVMD interventricular mechanical delay, SPWMD septal to posterior wall motion delay, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting enzyme, AT II angiotensine-II-receptor antagonist, K-sparing potassium sparing, NT-proBNP N-terminal pro-B-type natriuretic peptide